Sodium-glucose cotransporter 2 (SGLT2) inhibitors act to promote urinary glucose excretion and not only treat DM but also reduce inflammation, Na+/H+-exchange, and hyperuricemia. Here, SLC5A2 is linked to hyperuricemia.